S&P 500   3,852.36
DOW   32,920.46
QQQ   290.27
Mullen Automotive On Hiring Spree, What Could That Mean? 
Is This The End of Capitalism? (Ad)
What You Need to Know About Annuity Withdrawals
SoFi Technologies Smashes Earnings but Beware the Fed Decision
Become an Investor in Brooklyn Gin (Ad)pixel
Why Extreme Networks is a Recession-Proof Technology Play
Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
Is This The End of Capitalism? (Ad)
Grab Shares Are Suddenly On Track To Double
Buying The Dip In Colgate-Palmolive 
S&P 500   3,852.36
DOW   32,920.46
QQQ   290.27
Mullen Automotive On Hiring Spree, What Could That Mean? 
Is This The End of Capitalism? (Ad)
What You Need to Know About Annuity Withdrawals
SoFi Technologies Smashes Earnings but Beware the Fed Decision
Become an Investor in Brooklyn Gin (Ad)pixel
Why Extreme Networks is a Recession-Proof Technology Play
Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
Is This The End of Capitalism? (Ad)
Grab Shares Are Suddenly On Track To Double
Buying The Dip In Colgate-Palmolive 
S&P 500   3,852.36
DOW   32,920.46
QQQ   290.27
Mullen Automotive On Hiring Spree, What Could That Mean? 
Is This The End of Capitalism? (Ad)
What You Need to Know About Annuity Withdrawals
SoFi Technologies Smashes Earnings but Beware the Fed Decision
Become an Investor in Brooklyn Gin (Ad)pixel
Why Extreme Networks is a Recession-Proof Technology Play
Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
Is This The End of Capitalism? (Ad)
Grab Shares Are Suddenly On Track To Double
Buying The Dip In Colgate-Palmolive 
S&P 500   3,852.36
DOW   32,920.46
QQQ   290.27
Mullen Automotive On Hiring Spree, What Could That Mean? 
Is This The End of Capitalism? (Ad)
What You Need to Know About Annuity Withdrawals
SoFi Technologies Smashes Earnings but Beware the Fed Decision
Become an Investor in Brooklyn Gin (Ad)pixel
Why Extreme Networks is a Recession-Proof Technology Play
Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
Is This The End of Capitalism? (Ad)
Grab Shares Are Suddenly On Track To Double
Buying The Dip In Colgate-Palmolive 
NASDAQ:STOK

Stoke Therapeutics - STOK Stock Forecast, Price & News

$9.52
-0.11 (-1.14%)
(As of 01/30/2023 12:00 AM ET)
Add
Compare
Today's Range
$9.30
$9.61
50-Day Range
$7.07
$10.38
52-Week Range
$6.88
$26.60
Volume
69,935 shs
Average Volume
308,539 shs
Market Capitalization
$375.28 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$28.71

Stoke Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.71 Rating Score
Upside/​Downside
201.6% Upside
$28.71 Price Target
Short Interest
Bearish
16.17% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.59
Upright™ Environmental Score
News Sentiment
1.61mentions of Stoke Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.67) to ($2.90) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.88 out of 5 stars

Medical Sector

780th out of 1,049 stocks

Pharmaceutical Preparations Industry

391st out of 514 stocks


STOK stock logo

About Stoke Therapeutics (NASDAQ:STOK) Stock

Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. It offers a wide range of relevant tissues including the central nervous system, eye, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.

Receive STOK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Stoke Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

STOK Stock News Headlines

Expert Ratings for Stoke Therapeutics
Become an Investor in Brooklyn Gin
Award winning super-premium craft gin and upcoming Brooklyn distillerypixel
STOK Stoke Therapeutics, Inc.
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Stoke Therapeutics
See More Headlines
Receive STOK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Stoke Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

STOK Company Calendar

Last Earnings
11/14/2022
Today
1/30/2023
Next Earnings (Estimated)
3/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:STOK
Fax
N/A
Employees
102
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$25.17
High Stock Price Forecast
$35.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+201.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
6 Analysts

Profitability

Net Income
$-85,810,000.00
Pretax Margin
-1,093.04%

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.92 per share

Miscellaneous

Free Float
34,413,000
Market Cap
$375.28 million
Optionable
Not Optionable
Beta
0.38

Key Executives

  • Edward M. KayeEdward M. Kaye
    Chief Executive Officer & Director
  • Huw M. NashHuw M. Nash
    Chief Operating & Business Officer
  • Stephen J. Tulipano
    Chief Financial Officer
  • Barry S. TichoBarry S. Ticho
    Chief Medical Officer
  • Gene Liau
    Chief Scientific Officer













STOK Stock - Frequently Asked Questions

Should I buy or sell Stoke Therapeutics stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Stoke Therapeutics in the last twelve months. There are currently 1 sell rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" STOK shares.
View STOK analyst ratings
or view top-rated stocks.

What is Stoke Therapeutics' stock price forecast for 2023?

7 equities research analysts have issued 12 month target prices for Stoke Therapeutics' shares. Their STOK share price forecasts range from $9.00 to $50.00. On average, they predict the company's share price to reach $28.71 in the next twelve months. This suggests a possible upside of 205.8% from the stock's current price.
View analysts price targets for STOK
or view top-rated stocks among Wall Street analysts.

How have STOK shares performed in 2023?

Stoke Therapeutics' stock was trading at $9.23 at the beginning of 2023. Since then, STOK shares have increased by 1.7% and is now trading at $9.39.
View the best growth stocks for 2023 here
.

When is Stoke Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 9th 2023.
View our STOK earnings forecast
.

How were Stoke Therapeutics' earnings last quarter?

Stoke Therapeutics, Inc. (NASDAQ:STOK) posted its quarterly earnings data on Monday, November, 14th. The company reported ($0.66) EPS for the quarter, topping the consensus estimate of ($0.69) by $0.03. The firm had revenue of $2.91 million for the quarter, compared to analysts' expectations of $2.85 million.

What other stocks do shareholders of Stoke Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Stoke Therapeutics investors own include Gossamer Bio (GOSS), Editas Medicine (EDIT), Alector (ALEC), LogicBio Therapeutics (LOGC), NVIDIA (NVDA), Precision BioSciences (DTIL), Kaleido Biosciences (KLDO), Homology Medicines (FIXX), Marvell Technology (MRVL) and Invitae (NVTA).

When did Stoke Therapeutics IPO?

(STOK) raised $100 million in an initial public offering on Wednesday, June 19th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and Credit Suisse served as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is Stoke Therapeutics' stock symbol?

Stoke Therapeutics trades on the NASDAQ under the ticker symbol "STOK."

Who are Stoke Therapeutics' major shareholders?

Stoke Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.04%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Apple Tree Partners Iv, LP, Arthur Tzianabos, Barry Ticho, Edward M Md Kaye, Gene Liau, Huw M Nash, Huw M Nash, Robin A Walker and Stephen J Tulipano.
View institutional ownership trends
.

How do I buy shares of Stoke Therapeutics?

Shares of STOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Stoke Therapeutics' stock price today?

One share of STOK stock can currently be purchased for approximately $9.39.

How much money does Stoke Therapeutics make?

Stoke Therapeutics (NASDAQ:STOK) has a market capitalization of $370.15 million. The company earns $-85,810,000.00 in net income (profit) each year or ($2.61) on an earnings per share basis.

How many employees does Stoke Therapeutics have?

The company employs 102 workers across the globe.

How can I contact Stoke Therapeutics?

Stoke Therapeutics' mailing address is 45 WIGGINS AVENUE, BEDFORD MA, 01730. The official website for the company is www.stoketherapeutics.com. The company can be reached via phone at (781) 430-8200 or via email at ir@stoketherapeutics.com.

This page (NASDAQ:STOK) was last updated on 1/31/2023 by MarketBeat.com Staff